Logo image
Back
Functional Immunophenotyping for Precision Therapies in Sepsis
Journal article   Peer reviewed

Functional Immunophenotyping for Precision Therapies in Sepsis

Mahil Rao, Patrick W McGonagill, Scott Brackenridge, Kenneth E Remy, Charles C Caldwell, Richard S Hotchkiss, Lyle L Moldawer, Thomas S Griffith and Vladimir P Badovinac
Shock (Augusta, Ga.), Vol.63(2), pp.189-201
02/2025
DOI: 10.1097/SHK.0000000000002511
PMCID: PMC12447363
PMID: 39617419
url
https://pmc.ncbi.nlm.nih.gov/articles/PMC12447363/pdf/nihms-2110810.pdfView
Open Access

Abstract

Sepsis remains a significant cause of morbidity and mortality worldwide. While many more patients are surviving the acute event, a substantial number enter a state of persistent inflammation and immunosuppression, rendering them more vulnerable to infections. Modulating the host immune response has been a focus of sepsis research for the past fifty years, yet novel therapies have been few and far between. While many septic patients have similar clinical phenotypes, pathways affected by the septic event differ not only between individuals but also within an individual over the course of illness. These differences ultimately impact overall immune function and response to treatment. Defining the immune state - or endotype - of an individual is critical to understanding which patients will respond to a particular therapy. In this review, we highlight current approaches to define the immune endotype and propose that these technologies may be used to "pre-screen" individuals to determine which therapies are most likely to be beneficial.ABSTRACTSepsis remains a significant cause of morbidity and mortality worldwide. While many more patients are surviving the acute event, a substantial number enter a state of persistent inflammation and immunosuppression, rendering them more vulnerable to infections. Modulating the host immune response has been a focus of sepsis research for the past fifty years, yet novel therapies have been few and far between. While many septic patients have similar clinical phenotypes, pathways affected by the septic event differ not only between individuals but also within an individual over the course of illness. These differences ultimately impact overall immune function and response to treatment. Defining the immune state - or endotype - of an individual is critical to understanding which patients will respond to a particular therapy. In this review, we highlight current approaches to define the immune endotype and propose that these technologies may be used to "pre-screen" individuals to determine which therapies are most likely to be beneficial.
 Flow Cytometry Immunoparalysis endotype elispot hyperinflammation ELISA

Details

Metrics

16 Record Views
2 Times Cited - Web of Science
Logo image